Application of R19M, An FMC63 scFv Idiotype Monoclonal Antibody Anti-CD19 CAR-T cell therapy With the development of cancer immunotherapy, Chimeric AntigenReceptor (CAR)-T cell, which combines

Two CD19-specific CARs approved by US FDA in 2017 have induced prominent responses in patients with refractory leukemia and lymphomas. However, Grade 3/4 CRS and

Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven

Adaptor CAR platform advances It almost feels like a Christmas gift for CAR-T community even though December is still ten days to go. On November

Congratulations on professor Zhu’s new paper on Cytometry. We are to provide our products for tests!   https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.a.24676